CRISPR Therapeutics Stock Rises 1.29% on 228% Volume Jump, Ranked 298th in Market Activity

On August 13, 2025, CRISPR Therapeutics (CRSP) saw a 1.29% rise in its stock price with a trading volume of $400 million, a 228.17% increase from the previous day, ranking it 298th in market activity. The company remains focused on advancing gene-editing therapies for severe diseases, leveraging its CRISPR/Cas9 platform to develop treatments for hemoglobinopathies, oncology, and autoimmune conditions. Its lead candidate, CASGEVY, targets transfusion-dependent beta-thalassemia and sickle cell disease by editing hematopoietic stem cells to enhance fetal hemoglobin production.

CRISPR’s therapeutic pipeline includes autologous and allogeneic cell therapies, such as CTX112 and CTX131 for oncology, as well as in vivo programs addressing cardiovascular and metabolic disorders. Strategic collaborations with Vertex Pharmaceuticals and other biotech firms underscore its position in the gene-editing landscape. The company’s emphasis on ex vivo and in vivo gene-editing technologies positions it to capitalize on advancements in personalized medicine, though clinical progress and regulatory milestones will remain critical drivers for its stock performance.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to 2025 yielded a compound annual growth rate of 6.98%, with a maximum drawdown of 15.46% during the backtest period. The approach showed consistent growth over time but highlighted the risks of volatility, particularly during the market correction in mid-2023, underscoring the need for disciplined risk management in high-turnover trading environments.